Iovance Biotherapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Other eventsOct 5 →InsidersNo open-market buys or sales.→HoldersBlackRock 8.2%MHR Fund 6.4%State Street 5.4%→Financing →PeersClosest companies: REPL, TCRX, FATE→
From the filings
Figures
- Revenue
- $325.0Mlast 12 months
- Net income
- −$289.5Mlast 12 months
- Operating cash flow
- −$270.8Mlast 12 months
- Cash and equivalents
- $110.8Mat the last balance sheet
- Shares outstanding
- 453.0M shareson issue